Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes - 27/09/23
, Andrea Gramegna b, c, Laura Zazzeron d, Gianfranco Alicandro c, d, Laura L Porcaro a, Federica Piedepalumbo b, Chiara Lanfranchi d, Valeria Daccò d, Emanuela Orsi a, Francesco Blasi b, c
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Highlights |
• | We conducted this study to better understand the potential impact of ETI on glucose control, variability and body composition in patients with CFRD. |
• | We found a significant improvement in glucose control and a reduction in glucose variability after 6 months of ETI therapy, while insulin requirements remained unchanged. |
• | During the same period, we also observed a significant improvement in body mass index with an increase in body fat mass. |
• | Our results indicate a beneficial effect of ETI therapy on glucose metabolism in patients with CFRD, beyond the well-known effects on pulmonary function. |
Abstract |
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results.
We conducted a prospective observational study on 24 CF patients with CF-related diabetes requiring insulin therapy, with the aim to evaluate the effectiveness of ETI on glucose metabolism, glucose variability and body composition. After six months of treatment, HbA1c and coefficient of variation, measured through flash or continuous glucose monitoring, significantly decreased (median changes: -0.5, P = 0.029 and -6.3, P = 0.008, respectively), despite unchanged insulin requirements.
Over the treatment period, percent of fat mass increased by a median value of 3% (p = 0.029).
Il testo completo di questo articolo è disponibile in PDF.Keywords : Body composition, CFTR modulators, Cystic fibrosis, Diabetes, Glycaemic control
Mappa
Vol 49 - N° 5
Articolo 101466- settembre 2023 Ritorno al numero
Articolo precedente
- Serum albumin and risk of incident diabetes and diabetic microvascular complications in the UK Biobank cohort
- Yang-Wei Cai, Hai-Feng Zhang, Jing-Wei Gao, Zhao-Xi Cai, Jie-Wen Cai, Qing-Yuan Gao, Zhi-Teng Chen, Guang-Hong Liao, Chuan-Rui Zeng, Nuo Chen, Pin-Ming Liu, Jing-Feng Wang, Yang-Xin Chen
- Hyperglycemia-related anxiety during competition in an elite athlete with type 1 diabetes: A case report
- Alexandra Katz, Aidan Shulkin, Meryem K. Talbo, Asmaa Housni, Jane Yardley, Anne-Sophie Brazeau, Rémi Rabasa-Lhoret
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.